Sun Still Prowling For Acquisitions As It Sells Two US Plants
This article was originally published in PharmAsia News
Executive Summary
India's Sun Pharmaceutical Industries has said it is seeking "well-managed" acquisition targets -- unlike its 2015 purchase of troubled rival Ranbaxy which continues to absorb “significant” management time – at the same time as pressing ahead with its consolidation drive with the disposal of two US plants.